Published in Lancet on May 16, 1992
Coronary atheroma regression trials. Lancet (1992) 0.75
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet (1996) 7.73
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet (1995) 7.59
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 3.88
Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart (1999) 3.53
Local confidential inquiry into avoidable factors in deaths from stroke and hypertensive disease. BMJ (1993) 3.25
Dietary reduction of serum cholesterol concentration: time to think again. BMJ (1991) 3.10
Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) (1996) 2.88
Unemployment and psychological ill-health: the moderating role of duration and age. Psychol Med (1984) 2.82
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart (1999) 2.69
Investigation of selected patients with hypertension by the rapid-sequence intravenous urogram. Lancet (1992) 2.65
Unemployment and risk of minor psychiatric disorder in young people: cross-sectional and longitudinal evidence. Psychol Med (1982) 2.49
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
The Elag-Koln automatic blood pressure recorder. A clinical appraisal. Br Heart J (1977) 2.34
Adaptation of cough reflex with different types of stimulation. Eur Respir J (1992) 2.07
Fluorogenic substrate detection of viable intracellular and extracellular pathogenic protozoa. Science (1985) 2.07
Clinical evaluation of Dinamap 845 automated blood pressure recorder. Br Heart J (1980) 1.94
Sample size for short-term trials of antihypertensive drugs. Br J Clin Pharmacol (1982) 1.91
Predicting CHD risk in patients with diabetes mellitus. Diabet Med (2001) 1.91
A novel size-selective airborne particle size fractionating instrument for health risk evaluation. Ann Occup Hyg (2009) 1.75
The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed) (1984) 1.71
Weight reduction in a blood pressure clinic. Br Med J (1978) 1.67
Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther (1980) 1.64
Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. Clin Radiol (2002) 1.61
Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol (1982) 1.55
Subcutaneous herniation of gall-bladder with spontaneous cholecystocutaneous fistula. Clin Radiol (1990) 1.53
Persistent dry cough with enalapril: incidence depends on method used. J Hum Hypertens (1990) 1.50
Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses. Br J Clin Pharmacol (1975) 1.48
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet (1996) 1.40
Antihypertensive and adverse biochemical effects of bendrofluazide. BMJ (1990) 1.39
Liver dysfunction in hypertension. Lancet (1977) 1.35
Ketanserin in essential hypertension: a double-blind, placebo-controlled study. Postgrad Med J (1985) 1.32
Unemployment and psychological distress in young people: the moderating role of employment commitment. J Appl Psychol (1983) 1.30
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM (1999) 1.28
Quantification of side-effects of beta-adrenoceptor blockers using visual analogue scales. Br J Clin Pharmacol (1984) 1.24
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Factors influencing serum potassium in treated hypertension. Q J Med (1977) 1.22
The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens (1998) 1.21
Impact of venography on the diagnosis and management of deep vein thrombosis. Br Med J (Clin Res Ed) (1983) 1.15
Oral sustained-release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations. Br J Clin Pharmacol (1980) 1.14
Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol (1988) 1.12
A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol (1998) 1.12
Diuretic treatment of resistant hypertension. Br Med J (1980) 1.12
Preliminary evaluation of pinacidil in hypertension. Br J Clin Pharmacol (1983) 1.11
Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther (1982) 1.08
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine. Q J Med (1991) 1.08
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07
The association between haemospermia and severe hypertension. Postgrad Med J (1991) 1.07
Fatal pneumococcal meningitis in adults following splenectomy: two case reports and a review of the literature. J R Nav Med Serv (1973) 1.06
Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia. Br J Clin Pharmacol (1982) 1.04
Diuretic and beta-blocker in hypertension--then what? J R Coll Physicians Lond (1980) 1.03
Hydralazine once daily in hypertension. Br Med J (Clin Res Ed) (1982) 1.03
Bumetanide and frusemide: a comparison of dose-response curves in healthy men. Br J Clin Pharmacol (1978) 1.02
Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02
Restriction endonuclease analysis of Leishmania kinetoplast DNA characterizes parasites responsible for visceral and cutaneous disease. Am J Trop Med Hyg (1984) 1.00
Statins for primary prevention: at what coronary risk is safety assured? Br J Clin Pharmacol (2001) 0.98
Furosemide and bumetanide: a study of responses in normal English and German subjects. Clin Pharmacol Ther (1976) 0.98
ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. J Hum Hypertens (1995) 0.98
Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double-blind conditions. Br J Clin Pharmacol (1991) 0.97
Diagnosis of deep-vein thrombosis: comparison of clinical evaluation, ultrasound, plethysmography, and venoscan with X-ray venogram. Lancet (1984) 0.97
Severe disseminated intravascular coagulation associated with massive ventricular mural thrombus following acute myocardial infarction. Postgrad Med J (1988) 0.97
Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. Br J Clin Pharmacol (1995) 0.96
Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey. Heart (2001) 0.95
Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens (1994) 0.95
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol (1984) 0.94
Side-effects of beta-adrenoceptor blocking drugs assessed by visual analogue scales. Br J Clin Pharmacol (1985) 0.93
Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? J Hypertens Suppl (1996) 0.93
Should mild hypertension be treated with drugs? N Engl J Med (1980) 0.93